Идёт набор NCT06567418

Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients

— Наблюдательное Acute Coronary Syndrome

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: alirocumab 75mg/2week, statin ± ezetimibe.
Кому может быть актуально: Состояния в реестре: Acute Coronary Syndrome. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Китай
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients: A Database-based Retrospective Analysis

Обзор

The objective of this study is to investigate the effectiveness of in-hospital initiation of alirocumab combined with statin ± ezetimibe on major cardiovascular events (MACE) in Chinese ACS patients. The main question it aims to answer is: whether early initiation PCKS9i in hospital could reduce recent cardiovascular event risk in Chinese ACS patients in real-world setting. Data from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023. Patients diagnosed with STEMI, NSTEMI or UA at admission were identified at the first step. Then, for intervention group, patients who received alirocumab 75mg combined with statin ± ezetimibe during the ACS hospitalization (including the discharge date) will be included; for control group, patients who received statin ± ezetimibe during the ACS hospitalization will be included. All enrolled patients were required to have at least one documented follow-up visit.

Вмешательства

Препарат alirocumab 75mg/2week
patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
Препарат statin ± ezetimibe
patients will be censored at initiation of alirocumab during the follow up visit

Первичные конечные точки

The primary endpoint is the risk of MACE within 1 year of follow-up [Срок оценки: 12 months]

Вторичные конечные точки (2)

Percentage reduction of LDL-C levels at 1-month follow-up from baseline [Срок оценки: 1 month]
Proportion of patient who achieved LDL-C goal (<1.4mmol/L) at 1-month follow-up [Срок оценки: 1 month]

Критерии участия

Критерии включения

Patients diagnosed with Acute Coronary Syndrome (ACS) upon hospital admission.
Patients aged 18 years or older.
Patients who received Alirocumab 75 mg in combination with statin therapy ± Ezetimibe as the intervention group, and those treated exclusively with statin therapy ± Ezetimibe as the control group, either during hospitalization or at discharge.
Patients with at least one follow-up record.